Guardant Health released earnings earlier this month, disappointing investors with its sluggish revenue growth and increasing expenses.
News & Analysis: Guardant Health
GH earnings call for the period ending March 31, 2021.
Their liquid biopsies are giving doctors new and better tools to spot, track, and treat cancers.
The company's newest product received a key approval in New York.
Which healthcare company is a better play for the next decade?
This liquid biopsy pioneer is going after a huge potential market.
Innovation is risky, and these companies are all in.
The diagnostic testing company's growth may be slowing, but this shareholder isn't worried.
The overall stock market sell-off pulled Guardant Health's shares down.
The company reported disappointing Q4 results.